FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978768968> ?p ?o ?g. }

• W1978768968 endingPage "23" @default.
• W1978768968 startingPage "12" @default.
• W1978768968 abstract "Plasminogen activator inhibitor 1 (PAI-1) is the main physiological inhibitor of tissue-type and urokinase-type plasminogen activators (t-PA, u-PA). Endothelial or platelet-derived PAI-1 is normally complexed to vitronectin, which prolongs its half-life and makes it the most efficient inhibitor of activated protein C (APC) and thrombin, in the absence of heparin. These target proteinases share a positively charged surface loop (VR-1 or 37-loop), essential for rapid inactivation of the target enzymes. PAI-1 competes with thrombomodulin for binding this surface-loop in thrombin, which, in combination with APC inhibition, makes it a local procoagulant. Vitronectin enhances PAI-1 fibrin-binding, which prevents premature fibrinolysis but also compromises arterial, platelet-rich clot-lysis during pharmacological thrombolysis. Matrix-form vitronectin binds PAI-1 to regulate both u-PA induced pericellular proteolysis and integrin-substratum interactions, thereby influencing cell migration in angiogenesis, cancer and atherosclerosis. PAI-1 has not been established as an independent risk factor for various chronic cardiovascular diseases, caused by the many sites and pathways that integrate into PAI1 plasma levels. A vigorously increased PAI-1 level, however, results in local fibrin deposition in many inflammatory reactions and it strongly predicts the clinical outcome of sepsis by aggravating disseminated intravascular coagulation. Through its interactions with t-PA, thrombin, APC and thrombomodulin, elevated PAI-1 induces a local procoagulant state at the endothelial cell surface, which is aggravated in combination with other procoagulants like factor V-Leiden. The integrity of blood flow is under the continuous surveillance of the coagulation system, ensuring a rapid formation of fibrinstabilized blood clots at sites of injury to the vessel wall, thereby preventing excessive loss of blood from the circulation. Fibrin is formed from fibrinogen through limited proteolysis by thrombin. These thrombin-generated blood clots, however, need to be disposed of as soon as the damaged vessel wall has been repaired. Clot lysis is carried out by the serine protease plasmin, which cleaves multiple peptide bonds in the fibrin matrix, resulting in soluble fibrin degradation products thereby purging the supporting fibrin network of the clot, a process referred to as fibrinolysis. The activity of both coagulation and fibrinolysis needs to be finely tuned to prevent both premature or delayed clot formation and lysis. When bound to the endothelial surface protein thrombomodulin, thrombin also has anticoagulant activities through the protein C pathway, resulting in negative feedback inhibition (Esmon, 2000). Therefore both activation and subsequent inhibition of both thrombin and plasmin are tightly regulated in complex feedback regulatory loops, comprised of multiple zymogens, co-activators and inhibitors (Esmon, 2000). Active plasmin is formed from its inactive zymogen, plasminogen, by the specific proteolytic action of tissue-type plasminogen activator (t-PA). Plasminogen can also be activated by the urokinase-type plasminogen activator (uPA), which, in contrast to t-PA, is only marginally involved in clot-lysis because its presence and activity is mostly confined to tissues. Here, u-PA and plasmin are involved in the proteolysis of matrix proteins during processes like tissue repair and cell migration. The activities of both t-PA and u-PA are controlled by their specific inhibitor, plasminogen activator inhibitor-1 (PAI-1), the main topic of this review. PAI-1 was first purified as a protein secreted by endothelial" @default.
• W1978768968 created "2016-06-24" @default.
• W1978768968 creator A5088035975 @default.
• W1978768968 date "2004-02-17" @default.
• W1978768968 modified "2023-10-10" @default.
• W1978768968 title "Plasminogen activator inhibitor 1 (PAI-1):<i>in vitro</i>activities and clinical relevance" @default.
• W1978768968 cites W1445101152 @default.
• W1978768968 cites W1480134646 @default.
• W1978768968 cites W1493150376 @default.
• W1978768968 cites W1497473690 @default.
• W1978768968 cites W1503286274 @default.
• W1978768968 cites W151540657 @default.
• W1978768968 cites W1524068076 @default.
• W1978768968 cites W1550499229 @default.
• W1978768968 cites W157079418 @default.
• W1978768968 cites W1582391412 @default.
• W1978768968 cites W15890236 @default.
• W1978768968 cites W1589957034 @default.
• W1978768968 cites W1601891991 @default.
• W1978768968 cites W1607100760 @default.
• W1978768968 cites W1629173598 @default.
• W1978768968 cites W1652264878 @default.
• W1978768968 cites W167140354 @default.
• W1978768968 cites W1676144090 @default.
• W1978768968 cites W175798264 @default.
• W1978768968 cites W176430369 @default.
• W1978768968 cites W1851286093 @default.
• W1978768968 cites W1926488772 @default.
• W1978768968 cites W1961340888 @default.
• W1978768968 cites W1964052395 @default.
• W1978768968 cites W1969297665 @default.
• W1978768968 cites W1970314658 @default.
• W1978768968 cites W1971670006 @default.
• W1978768968 cites W1972292328 @default.
• W1978768968 cites W1973985157 @default.
• W1978768968 cites W1974208990 @default.
• W1978768968 cites W1976221474 @default.
• W1978768968 cites W1982730779 @default.
• W1978768968 cites W1984633053 @default.
• W1978768968 cites W1985686018 @default.
• W1978768968 cites W1991477778 @default.
• W1978768968 cites W1993376880 @default.
• W1978768968 cites W1995626607 @default.
• W1978768968 cites W1995786546 @default.
• W1978768968 cites W1995967510 @default.
• W1978768968 cites W2000985786 @default.
• W1978768968 cites W2002482145 @default.
• W1978768968 cites W2002811860 @default.
• W1978768968 cites W2005110412 @default.
• W1978768968 cites W2005121156 @default.
• W1978768968 cites W2005185823 @default.
• W1978768968 cites W2010102081 @default.
• W1978768968 cites W2011708104 @default.
• W1978768968 cites W2012076921 @default.
• W1978768968 cites W2013909807 @default.
• W1978768968 cites W2015806807 @default.
• W1978768968 cites W20164601 @default.
• W1978768968 cites W2022551990 @default.
• W1978768968 cites W2025586926 @default.
• W1978768968 cites W2031558257 @default.
• W1978768968 cites W2032102036 @default.
• W1978768968 cites W2038158926 @default.
• W1978768968 cites W2038969003 @default.
• W1978768968 cites W2041400348 @default.
• W1978768968 cites W2042742088 @default.
• W1978768968 cites W2044478331 @default.
• W1978768968 cites W2048045690 @default.
• W1978768968 cites W2049626340 @default.
• W1978768968 cites W2052371021 @default.
• W1978768968 cites W2052816027 @default.
• W1978768968 cites W2059305805 @default.
• W1978768968 cites W2060321450 @default.
• W1978768968 cites W2061346634 @default.
• W1978768968 cites W2062232597 @default.
• W1978768968 cites W2062969878 @default.
• W1978768968 cites W2064517965 @default.
• W1978768968 cites W2070627144 @default.
• W1978768968 cites W2078142004 @default.
• W1978768968 cites W2083945745 @default.
• W1978768968 cites W2084595805 @default.
• W1978768968 cites W2084876842 @default.
• W1978768968 cites W2091984324 @default.
• W1978768968 cites W2092903958 @default.
• W1978768968 cites W2094626757 @default.
• W1978768968 cites W2099283156 @default.
• W1978768968 cites W2102004159 @default.
• W1978768968 cites W2103201793 @default.
• W1978768968 cites W2104777086 @default.
• W1978768968 cites W2105114389 @default.
• W1978768968 cites W2109839308 @default.
• W1978768968 cites W2112455601 @default.
• W1978768968 cites W2114409101 @default.
• W1978768968 cites W2115715429 @default.
• W1978768968 cites W2123105612 @default.
• W1978768968 cites W2125002445 @default.
• W1978768968 cites W2125022615 @default.
• W1978768968 cites W2126655412 @default.
• W1978768968 cites W2131602901 @default.

• next